Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer

por Rakha, E A, Soria, D, Green, A R, Lemetre, C, Powe, D G, Nolan, C C, Garibaldi, J M, Ball, G, Ellis, I O
Publicado 2014

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer

por Alshareeda, A T, Negm, O H, Green, A R, Nolan, C C, Tighe, P, Albarakati, N, Sultana, R, Madhusudan, S, Ellis, I O, Rakha, E A
Publicado 2015

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers

por Green, A R, Powe, D G, Rakha, E A, Soria, D, Lemetre, C, Nolan, C C, Barros, F F T, Macmillan, R D, Garibaldi, J M, Ball, G R, Ellis, I O
Publicado 2013

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response

por Al-kaabi, M M, Alshareeda, A T, Jerjees, D A, Muftah, A A, Green, A R, Alsubhi, N H, Nolan, C C, Chan, S, Cornford, E, Madhusudan, S, Ellis, I O, Rakha, E A
Publicado 2015

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer

por Green, Andrew R., Soria, D., Powe, D. G., Nolan, C. C., Aleskandarany, M., Szász, M. A., Tőkés, A. M., Ball, G. R., Garibaldi, J. M., Rakha, E. A., Kulka, J., Ellis, I. O.
Publicado 2016